Search This Blog

Friday, December 8, 2023

Amneal and BIAL in U.S. Licensing Agreement for Parkinson's treatment

 

  • ONGENTYS® (opicapone) is a leading adjunctive therapy for the treatment of Parkinson’s Disease
  • Complements Amneal’s existing Parkinson’s franchise and further expands specialty portfolio
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)